Generics Bulletin: ジェネリック＆バイオシミラーニュース

EU Reforms Must Heed Pandemic Lessons

By David Wallace 08 Dec 2020

Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged

Topic Coronavirus EU Policy & Regulation

HBW Insight : コンシューマーヘルスケア産業のニュース

Lessons Learned: European Self-Care Industry Will Come Out Of Pandemic Stronger

By David Ridley 08 Dec 2020

Europe’s self-care industry has “learned its lessons,” particularly in terms of securing the pharmaceutical ingredient supply chain, and will come out of the coronavirus pandemic stronger, insisted AESGP president Birgit Schuhbauer at the BAH’s High-Level Conference on Future Drug Supply in the European Union.

Topic EU OTC Drugs Coronavirus

Generics Bulletin: ジェネリック＆バイオシミラーニュース

EU Reforms Must Heed Pandemic Lessons

By David Wallace 29 Nov 2020

Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.

Topic Coronavirus EU Policy & Regulation

HBW Insight : コンシューマーヘルスケア産業のニュース

Merz Consumer Care Optimistic About Future As German Lockdown Continues

By David Ridley 29 Nov 2020

Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure. 

Topic Coronavirus OTC Drugs EU

世界の薬事規制動向＆情報を配信

EU Countries Test Offering Simultaneous Scientific Advice

By Vibha Sharma 27 Nov 2020

An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.

Topic EU Innovation Regulation

世界の薬事規制動向＆情報を配信

Desperate Measures: How To Soften The Impact Of No-Deal Brexit

By Ian Schofield 27 Nov 2020

Building more cold chain warehouses, finding alternative sources of medicine supplies, and halting parallel exports to mitigate product shortages. Just some of the ideas for tackling the consequences of a no-deal Brexit scenario put forward by industry representatives at a recent parliamentary committee hearing.

Topic Pharma-Brexit Brexit EU